Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 22, 2025

FDA grants fast track status to Nacuity’s NPI-001 for retinitis pigmentosa

The US Food and Drug Administration (FDA) has granted fast track designation to Nacuity Pharmaceuticals’ NPI-001 (N-acetylcysteine amide) tablets for treating individuals with retinitis pigmentosa (RP).

FDA grants fast track status to Nacuity’s NPI-001 for retinitis pigmentosa